Litigation Fears Prompt Backlash to Labeling Rule

Generic Line
A group of generic drugmakers is proposing the FDA take the lead on initiating drug labeling changes prompted by adverse events, rather than relying on individual companies to initiate the changes.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00